ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "innate immunity"

  • Abstract Number: 0806 • ACR Convergence 2022

    Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression

    Inés Pérez Sancristóbal1, María Paula Álvarez Hernández2, Silvia Sanchez - Ramon3, Cristina Martinez4, Eduardo de la Fuente3, Concepcion Morado4, Dalifer Freites Nuñez2, Benjamin Fernandez Gutierrez5 and Gloria Candelas4, 1Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, 2Hospital Clínico San Carlos, Madrid, Spain, 3Department of Clinical Immunology, IML and IdSSC, Hospital Clínico San Carlos, Madrid, Spain, 4Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 5Hospital Clínico San Carlos, Rheumatology Deparment, Madrid, Spain

    Background/Purpose: Infections in patients with systemic autoimmune disease (SAD) are associated with immune dysfunction, disease activity and immunosuppression. Synthetic and biologic disease-modifying drugs (DMARDs) have…
  • Abstract Number: 1736 • ACR Convergence 2022

    IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells

    Tharshana Stephen1, Ambre Dangien1, Claire Leloup1, Ikram Mezghiche1, Laetitia Camard1, Hanan Yahia-Cherbal1, Vincent Guillemot2, Natalia Pietrosemoli1, Hélène Lopez-Maestre1, Julie Marsande1, Milena Hasan1, Dan Cua3, Anne Fourie4, Carrie Greving5, Raphaelle Parker6, Barbara Joyce Shaikh7, Bénédicte Oulès8, Sarah Guégan8, Sélim Aractingi8, Elisabetta Bianchi1 and Lars Rogge1, 1Institut Pasteur, Paris, France, 2Institut Pasteur, Paris, Ile-de-France, France, 3Janssen Research and Development, LLC, Spring House, PA, 4Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA, 5Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, 6Janssen Research & Development, Janssen-Cilag, Paris, France, 7Janssen Research & Development, LLC, San Diego, CA, 8Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Genome-wide association studies and mouse models of autoimmune disease have demonstrated an important role of the IL-23 signaling pathway in the pathogenesis of axial…
  • Abstract Number: 0975 • ACR Convergence 2022

    Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE

    Paul Newcombe1, Richard A. Furie2, Yoshiya Tanaka3, Wendy White4, Dominic Sinibaldi4, Philip Brohawn4, Mark Lazarus1, Nicola Ferrari1, Raj Tummala4, Hussein Al-Mossawi1, Andre Nogueria da Costa5, Daniel Muthas5 and Madhu Ramaswamy4, 1AstraZeneca, Cambridge, United Kingdom, 2Northwell Health, Great Neck, NY, 3University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 4AstraZeneca, Gaithersburg, MD, 5AstraZeneca, Gothenburg, Sweden

    Background/Purpose: SLE has been associated with expression of type I IFN gene signatures (IFNGS).1 Anifrolumab, a monoclonal antibody binding IFN receptor subunit 1, inhibits downstream…
  • Abstract Number: 1853 • ACR Convergence 2022

    A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease

    Mark Yun, Brianne Navetta-Modrov, Hafsa Nomani, Jie Yang and QingPing Yao, Stony Brook University, Stony Brook, NY

    Background/Purpose: NLRP3-associated autoinflammatoy disease (NLRP3-AID) and NLRP12-AID are rare autosomal dominant diseases. FACS1(familial cold autoinflammatory syndrome type 1), a subset of NLRP3-AID, is thought to…
  • Abstract Number: 1142 • ACR Convergence 2022

    The Lupus Risk Allele Associated Xq28 Haplotype Identifies the Molecular Endotype of a Cohort of European SLE Patients with Enhanced IRAK1 Signaling

    Rheyanna Clemens1, Tyson Dawson1, Katherine Owen2, Amrie Grammer3 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2RILITE, Crozet, VA, 3AMPEL LLC, Charlottesville, VA

    Background/Purpose: Previous genetic association studies identified a 9 gene region of Xq28 containing IRAK1 as a risk locus for SLE. IRAK1 plays key roles downstream…
  • Abstract Number: 1931 • ACR Convergence 2022

    NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis

    Esraa Eloseily1, Alexander Valencia2, Astha Malik2, Rebekah Karns2, Cyd Castro Rojas2, Mosab Alquraish2, Rebecca Marsh3, Alexei Grom4 and Alexander Miethke2, 1Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Gastroenterology, Hepatology & Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Division of Bone Marrow Transplantation & Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Mutations in the gene NOD2 encoding the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) which controls innate responses to LPS have been linked to Blau…
  • Abstract Number: 1177 • ACR Convergence 2022

    Identification of a New Type of Pro-phagocytic Macrophages in Patients with Systemic Sclerosis

    Amela Hukara1, Tracy Tabib2, Michal Rudnik1, Oliver Distler3, Przemyslaw Blyszczuk1, Robert Lafyatis2 and Gabriela Kania1, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 2Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland

    Background/Purpose: Phagocytosis is a crucial cellular process, which under certain immuno-pathological conditions can be activated in macrophages in an uncontrolled manner. Biomarker studies have implicated…
  • Abstract Number: 1936 • ACR Convergence 2022

    A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype

    Sara Alehashemi1, Adriana Almeida de Jesus2, Jonas Johannes Papendorf3, Farzana Bhuyan4, Kat Uss5, Anvitha Metpally6, Bin Lin7, Sophia Park8, Thais C.L. Moura9, Renata R Dias9, Mayra B. Dorna9, Katia Kozu9, Adriana Sallum9, Lucia M. A. Campos9, Gijs Santen10, Jesper Kers10, Onno Teng11, Karin Palmblad12, Tom Huizinga10, Frédéric Ebstein13, Elke Krüger13 and Raphaela Goldbach-Mansky14, 1NIH/NIAID/TADS, Clarksville, MD, 2NIAID, NIH, Silver Spring, MD, 3Institut für Medizinische Biochemie und Molekularbiologie, Universitätsmedizin Greifswald, Greifswald, Germany, 4National Institutes of Health, Bethesda, MD, 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 6NIAID, NIH, Bethesda, MD, 7NIH, Bethesda, MD, 8NIAID, Bethesda, MD, 9Children's Hospital of the University of São Paulo, São Paulo, Brazil, 10Leiden University Medical Center, Leiden, Netherlands, 11Leiden University Medical Center, Leiderdorp, Netherlands, 12Karolinska University Hospital, Stockholm, Sweden, 13Institut für Medizinische Biochemie und Molekularbiologie (IMBM), Universitätsmedizin Greifswald, Greifswald, Germany, 14NIH/NIAID, Potomac, MD

    Background/Purpose: Homozygote (HM)/compound heterozygote (CH) and digenic (DG) mutations in proteasome subunits cause the autoinflammatory syndrome CANDLE, or proteasome-associated autoinflammatory syndrome (PRAAS). Inflammation is mediated…
  • Abstract Number: 1327 • ACR Convergence 2022

    Immune Cell Subsets and Risk of Incident Hip Fracture in Older Adults: The Cardiovascular Health Study

    Rachel Elam1, Petra Buzkova2, Joseph Delaney3, Howard Fink4, Joshua Barzilay5, Laura Carbone1, Rick Saha1, John Robbins6, Kenneth Mukamal7, Rodrigo Valderrabano8, Bruce Psaty2, Russell Tracy9, Nels Olson9, Sally Huber10, Margaret Doyle9, Alan Landay11 and Jane Cauley12, 1Augusta University, Augusta, GA, 2University of Washington, Seattle, WA, 3University of Manitoba, Winnipeg, MB, Canada, 4University of Minnesota, Minneapolis, MN, 5Kaiser Permanente, Atlanta, GA, 6UC Davis, Davis, CA, 7Beth Israel Deaconess Medical Center, Boston, MA, 8Brigham and Women's Hospital, Boston, MA, 9University of Vermont, Burlington, VT, 10University of Vermont, Burlingon, VT, 11Rush University Medical Center, Chicago, IL, 12University of Pittsburgh, PIttsburgh, PA

    Background/Purpose: Cell-mediated immunity may play a role in osteoporosis development. Fracture is the major consequence of osteoporosis. Thus, cell-mediated immunity may impact fracture risk. We…
  • Abstract Number: 2051 • ACR Convergence 2022

    Targeting Janus Kinase Pathway in Sjogren’s Disease Corrects IFN-Driven Inflammation and Epithelial Dysfunction

    Sarthak Gupta1, Eiko Yamada2, Hiroyuki Nakamura2, Zohreh Khavandgar3, Daniel Martin2, Mayank Tandon4, Ilias Alevizos5, Shyh-Ing Jang2, Paola Perez2, Kalie Dominick2, Thomas Pranzatelli2, Alan Baer6, john chiorini4 and Blake Warner3, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2NIDCR, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4NIH, Bethesda, MD, 5Horizon Therapeutics, Gaithersburg, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Many of the inflammatory cytokines implicated in Sjogren's Disease (SjD) pathogenesis, in particular Type I and II interferons (IFNs), signal through Janus kinases (JAK)…
  • Abstract Number: 1565 • ACR Convergence 2022

    Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease

    Yesim Ozguler1, Ziyan Lin2, Ann Cavers3, gulen Hatemi4, Olivier Manches5 and Johannes Nowatzky3, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, 2NYU Grossman School of Medicine, NYU Langone Applied Informatics Laboratories, New York, NY, 3NYU Grossman School of Medicine, New York, NY, 4Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Recherche et Développement, Immunobiology and Immunotherapy in Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France

    Background/Purpose: Cellular immunity of Behçet's Disease (BD) remains poorly understood. Previous work has provided clues pointing to most innate and adaptive immune cell types in…
  • Abstract Number: 1663 • ACR Convergence 2022

    Age-Dependent Expansion and Activation of Disease-Associated Microglia in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

    Hadijat Makinde1, Caroline Shah1, Miranda Gurra1, Yidan Wang1, Deborah Winter2 and Carla Cuda1, 1Northwestern University, Chicago, IL, 2Northwestern University, Skokie, IL

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multipe end organs, including the brain. Despite a prevalence of over 50% in…
  • Abstract Number: 0025 • ACR Convergence 2022

    Wnt Pathway/Innate Immunity Equilibrium in OA Articular Cells

    Eloi Franco-Trepat1, Ana Alonso Pérez1, María Guillán-Fresco2, Miriam López Fagúndez1, Andrés Pazos-Pérez3, Antia Crespo Golmar4, María Piñeiro-Ramil5, Ana Lois Iglesias6, Alberto Jorge-Mora1 and Rodolfo Gomez1, 1MSP Group - Institute IDIS - CHUS - SERGAS, Santiago de Compostela, Spain, 2MSP Group - Institute IDIS - CHUS - SERGAS, Catoira, Spain, 3MSP Group - Institute IDIS - CHUS - SERGAS, Pontevedra, Spain, 4MSP Group - Institute IDIS - CHUS - SERGAS, León, Spain, 5MSP Group - Institute IDIS - CHUAC - SERGA, A Coruña, Spain, 6MSP Group - Institute IDIS - CHUAC - SERGAS, A Coruña, Spain

    Background/Purpose: The progressive degradation of osteoarthritis (OA) cartilage has been associated with articular innate immune responses (IIR) mediated by the Toll-like receptor 4 (TLR4). Additionally,…
  • Abstract Number: 1690 • ACR Convergence 2022

    Butyric Acid Suppresses Migration of Human Monocyte Derived Dendritc Cell by Inhibiting Actin Polymerization via mDia1 Inhibition

    Takumi Nagamoto1, takaichi okano2, Yoshikazu Fujikawa3, Yuzuru Yamamoto2, Hirotaka Yamada2, Yo Ueda2, Sho Sendo4 and Jun saegusa2, 1Kobe University, Kobe, Japan, 2Kobe University, Rheumatology, Kobe, Japan, 3Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan, 4University California, San Diego (UCSD), La Jolla, CA

    Background/Purpose: Butyric acid is known to improve chronic inflammation such as inflammatory bowel disease and arthritis. Dendritic cells activate in inflammatory condition, migrate to regional…
  • Abstract Number: 0049 • ACR Convergence 2022

    IL-18 Receptor-α Signaling Pathway Contributes to Autoantibody-induced Arthritis via Neutrophil Recruitment

    Shinjiro Kaieda and Tomoaki Hoshino, Kurume University School of Medicine, Kurume, Japan

    Background/Purpose: We have previously reported that IL-18 levels in the lungs, serum and bronchoalveolar lavage fluid (BALF) were increased in patients with idiopathic pulmonary lung…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology